Small molecules are abundant in nature, where they perform various roles in living cells, as enzyme cofactors, signaling molecules in biological networks or as metabolic components. As a consequence of physical interaction with proteins, they may illicit profound changes in protein function that can have physiological outcomes. Several biophysical and biochemical approaches, including high-throughput screening strategies, have been developed in an effort to globally or individually detect protein-metabolite interactions in vitro, in situ or in vivo. The use of affinity tags and protein overexpression has enabled the detection of metabolome-wide small molecule ligands of each protein target in turn. However, these methods are compounded by a necessity to isolate the protein target of interest from the cell, thus providing lesser physiological relevance and complicating downstream validation and analysis. Excluding the use of protein or small molecule arrays, the remaining in situ or in vivo approaches are limited to permit the identification of proteome-wide targets of each small molecule in turn. These technological restrictions translate to a bottleneck in data acquisition and difficulties in validation when determining important functional roles of small molecules in the context of biological networks. Therefore, currently, there are no technologies to globally identify the proteome-wide targets of all small molecules in live cells without isolation and disturbance of the intact targets within the intracellular milieu.
We aim to overcome this limitation by developing a new chemoproteomic technology that will permit direct isolation and characterization by mass spectrometry of metabolome-wide small molecules with their respective proteome-wide targets in situ in a single experiment. This truly global approach will deliver a powerful new tool for the investigator of protein-small molecule interactions by enabling the acquisition of the complete protein-metabolite interactome in live cells. We expect that the information gathered by adopting this technology will yield novel insights in small molecule-protein regulation, providing more comprehensive and larger biological networks for the analysis of signaling pathways of physiological relevance, and facilitating comparisons of entire organism protein-small molecule interactions under different experimental conditions in a similar manner to other current ?omics disciplines.

Public Health Relevance

Small molecules are ubiquitous in nature, diverse in chemical structure, performing various roles in the cell as active participants in cellular metabolism and most notably through their interactions with proteins, can serve as regulators of protein function. Current technologies are limited in their capacity to detect and catalog the entire complement of small molecules and the protein targets they may influence, in ways which have physiological and health consequences. Through the development of a new technology, designed to vastly increase the scale of detection of protein-bound small molecules, this proposal will greatly expand the capabilities of researchers in this emerging field, enabling a greater understanding of the regulatory roles of small molecules in biological networks, especially those of interest in human disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Exploratory/Developmental Grants (R21)
Project #
7R21GM126264-02
Application #
9878000
Study Section
Enabling Bioanalytical and Imaging Technologies Study Section (EBIT)
Program Officer
Smith, Ward
Project Start
2019-02-01
Project End
2021-01-31
Budget Start
2019-02-23
Budget End
2020-01-31
Support Year
2
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Pelian Biosciences, LLC
Department
Type
DUNS #
080168806
City
Sunnyvale
State
CA
Country
United States
Zip Code
94085